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Abstract
Background: Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of
the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has
been accomplished in chronic obstructive pulmonary disease through the use of patient completed diaries. These
tools may enhance exacerbation reporting and identification. The aim of this study was to develop a novel
symptom diary for bronchiectasis symptom burden and detection of exacerbations, named the BEST diary.
Methods: Prospective observational study of patients with bronchiectasis conducted at Ninewells Hospital, Dundee.
We included patients with confirmed bronchiectasis by computed tomography, who were symptomatic and had at
least 1 documented exacerbation of bronchiectasis in the previous 12 months to participate. Symptoms were
recorded daily in a diary incorporating cough, sputum volume, sputum colour, dyspnoea, fatigue and systemic
disturbance scored from 0 to 26.
Results: Twenty-one patients were included in the study. We identified 29 reported (treated exacerbations) and 23
unreported (untreated) exacerbations over 6-month follow-up. The BEST diary score showed a good correlation
with the established and validated questionnaires and measures of health status (COPD Assessment Test, r = 0.61,
p = 0.0037, Leicester Cough Questionnaire, r = − 0.52,p = 0.0015, St Georges Respiratory Questionnaire, r = 0.61,p <
0.0001 and 6 min walk test, r = − 0.46,p = 0.037). The mean BEST score at baseline was 7.1 points (SD 2.2). The peak
symptom score during exacerbation was a mean of 16.4 (3.1), and the change from baseline to exacerbation was a
mean of 9.1 points (SD 2.5). Mean duration of exacerbations based on time for a return to baseline symptoms was
15.3 days (SD 5.7). A minimum clinically important difference of 4 points is proposed.
Conclusions: The BEST symptom diary has shown concurrent validity with current health questionnaires and is
responsive at onset and recovery from exacerbation. The BEST diary may be useful to detect and characterise
exacerbations in bronchiectasis clinical trials.
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Introduction
Bronchiectasis is a chronic respiratory disease defined by
abnormal and irreversible dilatation of the bronchi [1].
The disease can be caused by many different aetiologies
and it is clinically characterised by a variety of symp-
toms, including cough, sputum production and airway
infection, and can often present with recurrent exacerba-
tions [2]. According to a recent international consensus
of experts, exacerbations are defined by an impairment
of at least 3 or more baseline symptoms including
cough, sputum volume and/or consistency, sputum
purulence, dyspnoea and/or exercise tolerance, fatigue
and/or malaise, haemoptysis for at least 48 h requiring a
change in treatment [3]. Recurrent exacerbations are re-
lated to elevated systemic and airway inflammation, de-
terioration of lung function and progression of the
disease [4–7]. As a consequence, exacerbations represent
one of the main causes of healthcare costs in bronchiec-
tasis. Some patients experience very frequent exacerba-
tions and these have been described a phenotype with a
higher morbidity and mortality [5]. Reduction of exacer-
bations is therefore, the key goal of most therapeutic in-
terventions [8].
Exacerbations have been the primary endpoints in the
majority of therapeutic phase 3 clinical trials in bronchi-
ectasis [9–11]. Unfortunately the results of recent trials
investigating inhaled antibiotics and inhaled mucoactive
drugs have given inconsistent results. The RESPIRE tri-
als for example, recruited patients with a history of at
least 2 exacerbations in the previous year, with the ex-
pectation they would experience a similar rate of exacer-
bations during follow-up. The rates in the four RESPIRE
studies in the placebo groups of 0.8, 1, 0.7 and 0.7 exac-
erbations per patient per year made it extremely difficult
to demonstrate a meaningful treatment effect [12].
Under-reporting and under-detection of exacerbations
may play a role in this phenomenon.
Improved reporting and detection of exacerbations, as
well as greater understanding of the natural history of
exacerbations has been achieved in Chronic obstructive
pulmonary disease through the use of patient completed
diaries [13]. These tools may enhance exacerbation
reporting and thereby identification [14], leading to
more efficient treatment when indicated. It has been
suggested that 2/3 of COPD exacerbations are not re-
ported to health care professionals [13, 15]. These are
important events to recognize using diaries because un-
reported exacerbations have been linked to a greater risk
of hospitalization, lung function deterioration, particu-
larly forced expiratory volume in 1 s (FEV1), and worse
St George’s respiratory questionnaire (SGRQ) scores
than treated exacerbations [15, 16].
The Exacerbations of chronic obstructive pulmonary
disease tool (EXACT) can detect the frequency,
duration and severity of exacerbations in patients with
COPD [13, 17].
The symptoms of COPD and COPD exacerbations are
similar but not identical to those of bronchiectasis. De-
velopment of a symptom diary specific for bronchiectasis
could provide substantial benefits for bronchiectasis re-
search by identifying events in clinical trials and provid-
ing detailed insight to bronchiectasis exacerbations,
including unreported events.
This manuscript describes the development and initial
validation of a novel symptom diary, the BEST diary
(Bronchiectasis Exacerbation and Symptoms Tool) to
detect bronchiectasis exacerbations.
Methods
This was a prospective observational study of adults
with bronchiectasis conducted at a specialist bronchi-
ectasis centre at Ninewells Hospital, Dundee, UK. The
study was approved by the local research ethics com-
mittee (13/ES/0062) and all patients gave written in-
formed consent to participate. Inclusion criteria
required high resolution CT (computerized tomog-
raphy) confirmed bronchiectasis; that bronchiectasis
was clinically significant with at least one of daily
cough, sputum production or a history of recurrent
respiratory tract infections and patients had to have
at least one documented exacerbation of bronchiec-
tasis in the previous 12 months to participate. Exclu-
sion criteria were age < 18 years, a primary diagnosis
of another respiratory condition (including co-existing
COPD and asthma) and cystic fibrosis. Patients had
to be clinically stable at enrolment for a period of at
least 4 weeks without treatment with antibiotics or
corticosteroids for an exacerbation. Receiving main-
tenance oral or inhaled antibiotics was permitted.
Development of a symptom diary
The study objective was to develop a symptom diary
that measures day to day changes in patient symp-
toms but also accurately detects exacerbations. The
study was conducted in parallel with the development
of the consensus definition of exacerbations by
EMBARC (European Multicentre Bronchiectasis Audit
and Research Collaboration). and the Bronchiectasis
Research Registry (EMBARC/Bronchiectasis Research
Registry- BRR) [3]. As previously reported, the au-
thors conducted a systematic review of definitions of
exacerbation used in previous studies in bronchiec-
tasis. The results of this systematic review are re-
ported in the EMBARC/BRR publication but were
also used for the development of this diary. Further
information about the results of the systematic review
are provided in the Additional file 1. As described in
the EMBARC/BRR publication, the symptoms most
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frequently used in prior definitions, and rated by Del-
phi process as most important were sputum volume,
cough, sputum colour, dyspnoea, fatigue and systemic
disturbance [3]. Patient self-report of an exacerbation
was also considered important in the Delphi process.
Based on these results and interviews with patients
who also identified the same critical symptoms [18],
we designed a daily diary that appropriately rated
these symptoms. The diary was modified with feed-
back from patients in terms of wording and clarity of
meaning until a final version was completed and de-
ployed in the study. For rating dyspnoea we incorpo-
rated the existing MRC dyspnoea score as it is
validated in bronchiectasis. The sputum colour do-
main followed the previously published scale by Mur-
ray et al which rates sputum from 1 to 4 ranging
from clear to dark green, with additional domains of
no sputum (0) and haemoptysis [5, 19]. The topic
“systemic symptoms” had little meaning to patients
and was modified to cold and flu symptoms. Quantifi-
cation of sputum volume using millilitres was also
regarded as difficult for most patients and so equiva-
lent volumes using teaspoon/tablespoon, egg-cup and
cup volumes were used. A teaspoon is equivalent to
5 ml, a tablespoon is equivalent to 15ml, egg-cup 45ml
and cup volume is approximately 250ml. The final diary
is shown in Table 1. The maximum score was 26.
Study design
Patients were asked to complete the diary every day for
a period of up to 6months while clinically stable and
then when they experienced an exacerbation. The pa-
tients were asked to contact the investigators when they
experienced an exacerbation so that treatment could be
commenced by the study team using a standard 14-day
course of antibiotics. The tool was not used to trigger
contact with the study team.
At the baseline visit patients were issued with the diary
and provided with education on its completion. Paper
diaries were used to avoid any bias in this population to-
wards those familiar with mobile technologies. Patients
completed the SGRQ, the COPD assessment test (CAT)
and the Leicester cough questionnaire (LCQ) at the
baseline visit. Patient enrolment took place in 2014 prior
to the development of the disease specific tools such
as the Quality of life bronchiectasis questionnaire
(QoL-B) or the Bronchiectasis Health Questionnaire
(BHQ) [20, 21]. Patients underwent spirometry and
performed a 6-min walk test (6MWT) to evaluate
convergent validity with these measures of lung func-
tion and functional status respectively. The assess-
ments were repeated at the start and end of each
exacerbation and finally at the end of study.
Validation of the symptom diary
We addressed firstly whether the symptom diary accur-
ately measured symptom burden in patients with bron-
chiectasis by demonstrating its convergent validity with
existing symptoms and quality of life (QOL) measures.
We hypothesised that the baseline symptom diary score
would correlate with the SGRQ total and symptom
scores, the LCQ, the COPD CAT and 6MWT. We next
analysed the dynamic changes in bronchiectasis symp-
toms over time. We hypothesised that symptom scores
would increase during periods of reported exacerbations.
To detect unreported exacerbations we required an in-
crease of at least 3 points in symptoms for a minimum
of 48 h based on the EMBARC/BRR definition of exacer-
bation [3]. An unreported exacerbation by definition was
associated with sustained increase in symptoms but did
not lead to a medical review or antibiotic treatment.
Table 1 The BEST (Bronchiectasis exacerbation and symptom
tool) diary card
BREATHLESSNESS FATIGUE
0 None 0 I do not feel tired
1 Breathlessness when
hurrying or walking up a
slight hill
1 I feel a little tired
2 Have to walk slowly on
level ground or stop for
breath after a few minutes
on level ground
2 I feel tired but can still do the things I
would like to do
3 Can walk less than 100m
or a few minutes on level
ground before having to
stop
3 Tiredness is stopping me from doing
some things I want to do
4 Breathless when washing
or dressing
4 I am so tired I am unable to carry out
my usual daily activities
SPUTUM VOLUME SPUTUM COLOUR
0 No sputum 0 No sputum
1 Less than a teaspoon 1 White
2 Teaspoon to an eggcup 2 Yellow
3 Egg-cup to a cup 3 Green
4 More than a cup 4 Dark Green
5 – 5 Blood stained
COUGH COLD AND FLU SYMPTOMS
0 None 0 None
1 Mild 1 Sore throat, sore muscles, or runny
nose
2 Moderate 2 Fever/high temperature or shivers
3 Severe 3 –
4 Very severe 4 –
5 – 5 I feel like a have an infection
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Calculation of the minimum clinically important
difference
We estimate a provisional minimum clinically important
difference for the BEST tool. As there is no single accepted
method of determining the minimal clinical important dif-
ference (MCID) we used 3 different approaches. First, the
distribution based method using ½ the standard deviation
of the scores for all participants. Second, if a correlation
coefficient of > 0.3 was achieved for the relationship with
scores which had an established MCID (such as the
SGRQ, CAT and LCQ) we would use these as an “anchor”
to estimate the change in BEST score that equated to a
clinically meaningful change in the other tool. Finally as a
reported exacerbation is a clinically meaningful change in
symptoms, we would consider the change in BEST at
exacerbation onset as a potential MCID [22].
Statistical analysis
Statistical analysis was performed using Graphpad Prism
v6 and SPSS version 22 (IBM, USA). Categorical variables
are presented by frequencies and percentages while con-
tinuous variables are presented as mean and standard de-
viation (SD) or median and interquartile range (IQR)
when data are not distributed normally. The relationship
between the diary scores and quality of life/symptom mea-
sures such as SGRQ, CAT, LCQ and 6MWT were per-
formed by linear regression. The regression equation was
used to calculate the change in BEST score that would
equate to the MCID scores of 4 points in the SGRQ, 2
points in the CAT and 1.3 points in the LCQ [22, 23]. Stu-
dents T-test was used to compare means between differ-
ent time points such as stability and exacerbation. Stability
of symptoms within individual patients was evaluated with
the within subject standard deviation and the coefficient
of variation. To establish patients’ baseline level of symp-
toms we took the median value in the week prior to an
event (or in the first week of the study). As this was a pilot
study, no formal sample size calculation was performed
and the objective was to enrol 20 patients to get initial ex-
perience with the tool. For all analyses a p-value < 0.05
was considered statistically significant.
Results
Description of the patients
Twenty-one patients were included. All patients had
idiopathic or post-infective bronchiectasis. The charac-
teristics of the patients are shown in Table 2. Patients
had predominantly moderate to severe bronchiectasis
and in common with most bronchiectasis populations,
were elderly and female. As the study enrolled patients
with a history of exacerbations the mean exacerbation
and use of prophylactic therapies such as macrolides was
high in this cohort.
Nineteen patients completed the diary daily for at least
3 months. One patient had an exacerbation within the
first week of starting the diary and did not persist with
completion following exacerbation resolution, while an-
other patient completed 6 weeks without an exacerbation
and then ceased to adhere consistent data entry. Baseline
data for the BEST are therefore shown for n = 21 patients
while dynamic changes over time are analysed for N = 19
who had available long term data.
Validation of symptom diary through correlation with
other measures of health status
At baseline, all patients completed the SGRQ, LCQ, CAT
questionnaires and performed a 6MWT as measures of
health status. The relationship between the baseline BEST
score and the established measures of health status are
shown in Fig. 1. The correlation with the CAT score (Fig.
1a) was r = 0.61, p = 0.0037. A significant correlation was
also detected between the BEST score and the SGRQ total
score (r = 0.61, p < 0.0001), Fig. 1b, 6MWT (r = − 0.46, p =
0.037,Fig. 1c), LCQ score (r = − 0.52,p = 0.015), Fig. 1d, and
the symptom domain of the SGRQ (r = 0.52, p = 0.015),
Table 2 Characteristics of the included patients
Characteristic Mean (sd) or n (%)
Age 67.5 (7.4)
Female sex 16 (76.2%)
Comorbidities
Cardiovascular disease 1 (4.8%)
Osteoporosis 4 (19.1%)
Anxiety/depression 3 (14.3%)
Diabetes 2 (9.5%)
FEV1 1.76 (0.60)
FEV1% predicted 78.7% (21.7)
FVC 2.74 (0.87)
Bronchiectasis severity index
Mild 4 (19.0%)
Moderate 10 (47.6%)
Severe 7 (33.3%)
Prior exacerbations 3.3 (2.0)
Treatment
Inhaled corticosteroids 11 (52.4%)
Macrolides 12 (57.1%)
Inhaled antibiotics 1 (4.8%)
Baseline quality of life and functional status
6 min walk distance 439 (104)
CAT score 19.1 (6.1)
SGRQ 41.5 (17.0)
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A 4-point change in the SGRQ is regarded as clinically
significant. The above correlation suggested that a
change of 3.5 points in the BEST symptom diary was
equivalent to a 4-point change in the SGRQ. For the
LCQ, a 1.3-point change is regarded as clinically signifi-
cant, and this correlated to a 4.95-point change in the
BEST score. A clinically significant 2-point change in
the CAT required a 4-point change in the BEST symp-
tom diary. Taking a cut-off of 4 points, the change in
BEST score had a sensitivity of 93% and specificity of
66% for detection of treated exacerbations. Raising the
threshold to 5 points had a sensitivity of 86% and speci-
ficity of 81%. At 6 points the sensitivity declined to 79%
with specificity of 82%.
Dynamic changes in symptoms over time and detection
of exacerbations
Figure 2 below shows the dynamics of symptoms over
time for 19 patients who were able to complete the diar-
ies consistently for at least 3 months. In the figure below,
the patient reported exacerbations are identified with a
red box. 29 exacerbations in total were reported during
the study.
The mean BEST score at baseline was 7.1 points (SD
2.2). Symptoms generally increased over several days prior
to the diagnosis of an exacerbation. The mean score during
this “pre-exacerbation” period was 11.3 points (SD 2.7) with
a mean change of + 4 points (SD 1.8) (p < 0.0001 by paired
t-test). The peak symptom score during exacerbation was a
mean of 16.4 (3.1) (range 12–22). The change from baseline
was a mean of 9.1 points (SD 2.5) with a range of 5 to 14.
Interestingly 7 out of 29 exacerbations (24%) reported by
the patients did not meet the EMBARC/BRR definition be-
cause of the presence of only 1 or 2 symptoms.
Based on the time taken for the symptom score to return
to the baseline level post-exacerbation, symptoms remained
elevated for 15.3 days after exacerbation diagnosis (SD 5.7).
The range of recovery time was 5 days to 28 days.
Unreported exacerbations and symptom variability
Based on a sustained increase in 3 points for at least 48 h,
we identified 23 unreported exacerbations in 13 patients.
No patients received antibiotic treatment during periods
of unreported exacerbations. 8 patients had no unreported
exacerbations. The mean change from baseline in an unre-
ported exacerbation was 4.7 (SD 1.5, range 3–8 points).
The mean duration of unreported exacerbations was 10
days (SD 3.8). Unreported exacerbations were therefore
significantly milder and shorter than reported exacerba-
tions. The end of the unreported exacerbation was consid-
ered when the score returned to pre-exacerbation baseline
level. The sample size was too small to establish any rela-
tionships between unreported exacerbations and clinical
outcomes.
We observed that some patients had relatively stable
symptoms over time while others showed remarkable day
to day variability in symptom scores. The coefficient of vari-
ation in symptom scores, excluding exacerbation periods,
ranged from 16.1 to 97.8%. No relationship was observed
Fig. 1 Correlations between the baseline BEST score and existing methods of evaluating symptoms and functional status a: CAT score, b:
SGRQtotal score, c: 6-min walk distance, d: Leicester cough questionnaire (LCQ), e: Symptom domain of the SGRQ
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between the co-efficient of variation or the within subject
standard deviation and patient characteristics (Table 3).
Provisional minimum clinically important difference
The correlation with the SGRQ and CAT scores sug-
gested an MCID of 4 points would be consistent with a
clinically important change in other tools. Using the ½
standard deviation method to calculate the MCID sug-
gested a smaller MCID of 2.2 points. Exacerbation onset
was associated with a change of 4 points as described
above. Based on the majority of data available we
propose an initial MCID of 4 points.
Discussion
The most relevant findings of our study were as follows:
I) a newly developed symptom diary (hereafter referred
to as the BEST tool) showed a good correlation with the
established and widely validated questionnaires and
measures of health status, including CAT, LCQ, SGRQ
and 6MWT. II) Patients experienced a statistically
significant increase in symptoms prior to reporting an
exacerbation and the diary detected a large increase in
symptoms during acute exacerbations requiring anti-
biotic treatment. III) After an exacerbation, symptoms
remained elevated for 15.3 days (SD 5.7) before returning
to the pre-exacerbation baseline level IV) 23 unreported
exacerbations were identified in our cohort. To the au-
thors knowledge this is the first description of unre-
ported exacerbations in bronchiectasis. These events
were significantly shorter and milder than reported ex-
acerbation events V) We report a provisional MCID for
the BEST tool with a suggestion that a 4-point change
may be a clinically meaningful change in symptoms. The
BEST tool now requires broader validation in larger pa-
tient cohorts. The diary is simple to complete and can
be completed on paper or is easily adaptable to an appli-
cation for electronic devices.
A validated symptom diary could be useful in the de-
tection of exacerbations in the context of clinical re-
search studies as well as randomized clinical trials. To
Fig. 2 Individual patient dynamics during the study. The x-axis shows the time in the study which each point representing a single days score.
The Y-axis shows the BEST score
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the best of our knowledge, this is the first study to valid-
ate a symptom diary in bronchiectasis patients. Our
symptom diary showed a statistically significant correl-
ation with widely validated health status measures [24].
During the study period 29 exacerbations were reported.
In our study, BEST symptom diary enabled the measure-
ment of day to day changes in symptomatic bronchiec-
tasis patients and allowed the detection of the onset,
peak and duration of exacerbations. While some studies
have used quality of life tools such as the Quality of life
bronchiectasis questionnaire to study the change in
symptoms at the time of an exacerbation, these tools
compare a measure of symptoms at one time point,
often remote from the exacerbation by months, and a
change at a single time point in the exacerbation which
may be not be the peak of symptoms [20]. The QOL-B
questionnaire has a 1 week recall period. Our data shows
that symptoms are highly variable and dynamic in bron-
chiectasis patients. The earliest detectable change at the
onset of an exacerbation was a mean 4-point deterior-
ation in the score, but the peak of symptoms was much
higher at a mean of 9 points.
Symptom diaries show some advantages over trad-
itional QoL tools. Some of the traditional QoL tools
show considerable complexity in their completion. The
SGRQ, which is a widely used and validated question-
naire, consists of multiple sections and domains [25].
The QoL-B is more simple and the respiratory symptom
domain consists of only 9 questions, but was not designed
to detect exacerbations or quantify their severity [20]. Re-
cently developed tools such as the BHQ are also designed
to be static measures of disease burden rather than dy-
namic [21]. The majority of QOL questionnaires have a
recall period asking about symptoms over the last week,
last month or even 3months. One of our most striking
findings was the large day to day variation in symptoms in
many patients even in the absence of an exacerbation. Evi-
dence of such variability suggests there may be a loss in
the accuracy of the symptoms that patients report through
traditional QoL questionnaires or that patients could find
difficulties in deciding which symptoms to report.
One of the most interesting and important findings in
our study is around the dynamics of reported exacerbation.
We showed that there is often a period of increased symp-
toms prior to the reporting of an exacerbation. This is im-
portant as it suggests a period where exacerbation events
may be aborted with appropriate measures. We speculate
that such measures might include an increase in the fre-
quency and intensity of airway clearance. Knowledge that
there is a pre-exacerbation period where inflammation in-
creases has been used to successfully target anti-
inflammatory therapy to prevent exacerbations in asthma
[26]. This knowledge is therefore potentially useful in fu-
ture trials for bronchiectasis. A high variability was ob-
served in the severity and duration of the exacerbations
in our cohort of patients with a range of 12–22 points
in the symptom score and a range of 5 to 28 days in the
duration of the exacerbations respectively. This data is
also useful as this cohort collected data on what would
be considered “mild” or “moderate” community treated
exacerbations and yet the symptoms persisted for more
than 2 weeks and in some cases a month. This is im-
portant information as the severity and impact of exac-
erbations is often underestimated. Our study did not
include hospitalized severe exacerbations which might
be expected to have longer and more severe symptoms.
It has been observed in COPD patients, that failure
to report exacerbations is related to higher risk of
emergency department and hospital admission, greater
lung function deterioration, and worse SGRQ scores
than treated exacerbations and thus, may result in a
poorer prognosis when compared to treated exacerba-
tions [13–16]. Improved reporting and detection of
exacerbations has been achieved in COPD through
the use of patient completed diaries. To the authors
knowledge our study is the first to characterise unre-
ported and untreated exacerbations in bronchiectasis.
Twenty-three unreported exacerbations were noted
among 13 patients during the period of study. The
peak symptom score during unreported exacerbations
was a mean of 11, while the mean duration was 10
days (SD 3.8), showing that unreported exacerbations
were milder and shorter than reported ones but
nevertheless had an important impact on patients. Al-
though unreported exacerbations appeared to be milder,
they may still be important in terms of health repercus-
sion. This was observed in the ATTAIN study where un-
reported exacerbation in COPD patients had the same
medium-term health consequences as reported HCRU
exacerbations [27]. Further studies are needed in bronchi-
ectasis patients to discern whether these unreported exac-
erbations are relevant.
As aforementioned, we detected 23 unreported and 29
reported exacerbations during the study period using the
BEST symptom diary. The unreported events repre-
sented 44% of the total exacerbations. This suggests the
use of symptom diaries in bronchiectasis clinical trials
Table 3 Differences between reported and unreported
exacerbations. Onset time: number of days prior to
commencing antibiotics
REPORTED
EXACERBATIONS
UNREPORTED
EXACERBATIONS
Onset time (days) 4.8 (SD 3.5) Not applicable
Change from
baseline
9.1 (SD 2.5) 4.7 (SD 1.5)
Peak score 16.4 (SD 3.1) 11.1 (SD 3.0)
Duration 15.3 days 10 days
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would provide an increased ability to detect both re-
ported and unreported events with a better comprehen-
sion of the natural behaviour of the disease, and thereby
contribute to an improvement in bronchiectasis re-
search. Many recent bronchiectasis clinical trials have
been underpowered due to a failure to capture the ex-
pected number of exacerbations during the course of
studies [9–12]. There are many reasons for this
phenomenon including placebo effects and the Haw-
thorne effect, but future trials urgently need to take
measures to ensure they are adequately powered.
We reported a provisional MCID for the BEST tool in
our study based on distribution and anchor based methods.
As our sample size is small and the methods used sug-
gested an MCID from 2 to 5 further research is required to
establish the true MCID. Nevertheless, our analysis suggests
that a change in score of 4 points may be clinically mean-
ingful with a sustained worsening of the score by 4 points
or more for 48 h indicative of exacerbation.
The major limitation of our study was the small sam-
ple size. Other limitations were the single-centre design
of the study and that data collection was conducted for a
maximum of 6 months. Diaries place a significant bur-
den on participants by expecting them to complete the
information on a daily basis and larger and longer stud-
ies would be needed to monitor adherence over for ex-
ample a 12 month randomized trial. This was a pilot
study focused on the development and validation of the
tool. Future studies with a large sample size are now re-
quired to demonstrate the capability of the tool to im-
prove exacerbation detection, to establish the clinical
significance of unreported exacerbations and to under-
stand whether day to day fluctuations in patient symptoms
contribute to morbidity and mortality. Incorporation of
diaries into clinical trials could provide invaluable infor-
mation on how therapies affect patients’ symptoms in a
far more detailed way than is currently captured.
Conclusions
The BEST symptom diary shows convergent validity
with existing health questionnaires and is responsive at
onset and recovery from exacerbation. A daily diary such
as BEST may be useful to capture and characterise exac-
erbations in future trials.
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